**Supplemental Digital Content** **Table 1. Baseline Demographic and Glabellar Line Characteristics, by Fitzpatrick Skin Type and Race (N=492)**

| **Characteristic, n (%)** | **Fitzpatrick Skin Type** |  | **Fitzpatrick Skin Type Subset** |
| --- | --- | --- | --- |
| **+SOC (N=140)** |  | **–SOC (N=352)** |  | **+SOC Black (N=37)** |  | **–SOC White (N=345)** |
| Female | 124 | (88.6) |  | 323 | (91.8) |  | 33 | (89.2) |  | 317 | (91.9) |
| <65 | 134 | (95.7) |  | 305 | (86.6) |  | 34 | (91.9) |  | 300 | (87.0) |
| White | 75 | (53.6) |  | 345 | (98.0) |  | 0 | (0.0) |  | 345 | (100.0) |
| Black/African American | 37 | (26.4) |  | 0 | (0.0) |  | 37 | (100.0) |  | 0 | (0.0) |
| Asian, Multiple or Other  | 28 | (20.0) |  | 7 | (2.0) |  | 0 | (0.0) |  | 0 | (0.0) |
| Skin Types I+II+III | 0 | (0.0) |  | 352 | (100.0) |  | 0 | (0.0) |  | 345 | (100.0) |
| Skin Types IV+V+VI | 140 | (100.0) |  | 0 | (0.0) |  | 37 | (100.0) |  | 0 | (0.0) |
| GLS Score of Moderate at Maximum Frown by IA  | 33 | (23.6) |  | 87 | (24.7) |  | 13 | (35.1) |  | 86 | (24.9) |
| GLS Score of Severe at Maximum Frown by IA | 107 | (76.4) |  | 265 | (75.3) |  | 24 | (64.9) |  | 259 | (75.1) |
| Prior Botulinum Toxin Exposure | 42 | (30.0) |  | 152 | (43.2) |  | 6 | (16.2) |  | 149 | (43.2) |

SOC=skin of color; GLS=Glabellar Line Scale (0=no lines, 1=mild, 2=moderate, 3=severe); IA=investigator assessment.

Supplemental Digital Content Table 2. Percentage of Responders Based on a ≥1-Point Improvement on the GLS at Maximum Frown from Day 0, by Fitzpatrick Skin Type and Race, by Visit (N=492)

| **Day** | **Fitzpatrick Skin Type**  |  | **Fitzpatrick Skin Type Subset** |
| --- | --- | --- | --- |
| **+SOC (N=140)** | **–SOC (N=352)** | **% Difference (95% CI)** | **P-Value** |  | **+SOC Black (N=37)** | **–SOC White (N=345)** | **% Difference (95% CI)** | **P-Value** |
| 2 | 47.0 | 52.8 | -5.8 (-15.8, 4.5) | 0.291 |  | 45.5 | 52.8 | -7.3 (-25.3, 12.0) | 0.657 |
| 7 | 88.0 | 92.1 | -4.2 (-11.5, 1.7) | 0.287 |  | 88.6 | 92.0 | -3.4 (-19.9, 5.1) | 0.796 |
| 14 | 91.8 | 96.2 | -4.4 (-10.8, 0.2) | 0.082 |  | 88.2 | 96.2 | -7.9 (-24.5, 1.0) | 0.077 |
| 30 | 94.0 | 96.0 | -2.0 (-7.9, 2.1) | 0.401 |  | 85.3 | 95.9 | -10.6 (-27.8, 0.1) | 0.075 |
| 90 | 72.1 | 80.5 | -8.4 (-17.8, 0.7) | 0.080 |  | 80.6 | 80.2 | 0.5 (-19.1, 12.7) | >0.999 |
| 120 | 55.5 | 63.2 | -7.7 (-18.0, 2.7) | 0.243 |  | 71.9 | 63.1 | 8.8 (-11.5, 23.7) | 0.464 |
| 150 | 31.5 | 40.1 | -8.6 (-17.9, 1.8) | 0.107 |  | 43.8 | 39.9 | 3.8 (-14.5, 23.2) | >0.999 |

SOC=skin of color; +SOC=Fitzpatrick skin types IV+V+VI; –SOC=Fitzpatrick skin types I+II+III; GLS=Glabellar Line Scale (0=no lines, 1=mild, 2=moderate, 3=severe).

Supplemental Digital Content Table 3. Summary of Treatment-Related Adverse Events, by Fitzpatrick Skin Type and Race (N=492)

| **Adverse Event Parameter** | **Fitzpatrick Skin Type**  |  | **Fitzpatrick Skin Type Subset** |
| --- | --- | --- | --- |
| **+SOC (N=140)** |  | **–SOC (N=352)** |  | **+SOC Black (N=37)** |  | **–SOC White (N=345)** |
|  **n** |  **(%)** | **E** |  |  **n** |  **(%)** | **E** |  |  **n** |  **(%)** | **E** |  |  **n** |  **(%)** |  **E** |
| Any TR AE | 20 | (14.3) | 27 |  | 42 | (11.9) | 62 |  | 5 | (13.5) | 9 |  | 39 | (11.3) | 58 |
| Most Common TR AEs (>1%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Headache | 17 | (12.1) | 22 |  | 29 | (8.2) | 31 |  | 5 | (12.5) | 8 |  | 27 | (7.8) | 29 |
|  Eyelid ptosis | 0 | (0.0) | 0 |  | 5 | (1.4) | 5 |  | 0 | (0.0) | 0 |  | 4 | (1.2) | 4 |
| Any TR AE of Particular Interest | 0 | (0.0) | 0 |  | 7 | (2.0) | 11 |  | 0 | (0.0) | 0 |  | 6 | (1.7) | 9 |
|  Eyelid ptosis | 0 | (0.0) | 0 |  | 5 | (1.4) | 5 |  | 0 | (0.0) | 0 |  | 4 | (1.2) | 4 |
|  Brow ptosis | 0 | (0.0) | 0 |  | 2 | (0.6) | 3 |  | 0 | (0.0) | 0 |  | 2 | (0.6) | 3 |
|  Vision blurred | 0 | (0.0) | 0 |  | 2 | (0.6) | 2 |  | 0 | (0.0) | 0 |  | 1 | (0.3) | 1 |
|  Diplopia | 0 | (0.0) | 0 |  | 1 | (0.3) | 1 |  | 0 | (0.0) | 0 |  | 1 | (0.3) | 1 |

SOC=skin of color; +SOC=Fitzpatrick skin types IV+V+VI; –SOC=Fitzpatrick skin types I+II+III; AE=adverse event; E=Events; TR=treatment related.